{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:56:26Z","timestamp":1791896186565,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Precision Biologics, Inc"},{"name":"National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>NEO201 is a humanized IgG1 monoclonal antibody (mAb) generated against tumor-associated antigens from patients with colorectal cancer. NEO-201 binds to core 1 or extended core 1 O-glycans expressed by its target cells. Here, we present outcomes from a phase I trial of NEO-201 in patients with advanced solid tumors that have not responded to standard treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single site, open label 3\u2009+\u20093 dose escalation clinical trial. NEO-201 was administered intravenously every two weeks in a 28-day cycle at dose level (DL) 1 (1\u00a0mg\/kg), DL 1.5 (1.5\u00a0mg\/kg) and DL 2 (2\u00a0mg\/kg) until dose limiting toxicity (DLT), disease progression, or patient withdrawal. Disease evaluations were conducted after every 2 cycles. The primary objective was to assess the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of NEO-201. The secondary objective was to assess the antitumor activity by RECIST v1.1. The exploratory objectives assessed pharmacokinetics and the effect of NEO-201 administration on immunologic parameters and their impact on clinical response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventeen patients (11 colorectal, 4 pancreatic and 2 breast cancers) were enrolled; 2 patients withdrew after the first dose and were not evaluable for DLT. Twelve of the 15 patients evaluable for safety discontinued due to disease progression and 3 patients discontinued due to DLT (grade 4 febrile neutropenia [1 patient] and prolonged neutropenia [1 patient] at DL 2, and grade 3 prolonged (&gt;\u200972\u00a0h) febrile neutropenia [1 patient] at DL 1.5). A total of 69 doses of NEO-201 were administered (range 1\u201315, median 4). Common (&gt;\u200910%) grade 3\/4 toxicities occurred as follows: neutropenia (26\/69 doses, 17\/17 patients), white blood cell decrease (16\/69 doses, 12\/17 patients), lymphocyte decrease (8\/69 doses, 6\/17 patients). Thirteen patients were evaluable for disease response; the best response was stable disease (SD) in 4 patients with colorectal cancer. Analysis of soluble factors in serum revealed that a high level of soluble MICA at baseline was correlated with a downregulation of NK cell activation markers and progressive disease. Unexpectedly, flow cytometry showed that NEO-201 also binds to circulating regulatory T cells and reduction of the quantities of these cells was observed especially in patients with SD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NEO-201 was safe and well tolerated at the MTD of 1.5\u00a0mg\/kg, with neutropenia being the most common adverse event. Furthermore, a reduction in the percentage of regulatory T cells following NEO-201 treatment supports our ongoing phase II clinical trial evaluating the efficiency of the combination of NEO-201 with the immune checkpoint inhibitor pembrolizumab in adults with treatment-resistant solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03476681\">NCT03476681<\/jats:ext-link>\n                      . Registered 03\/26\/2018.\u00a0\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-023-02649-6","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T03:03:56Z","timestamp":1680059036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors"],"prefix":"10.1186","volume":"42","author":[{"given":"Christopher B.","family":"Cole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8164-2587","authenticated-orcid":false,"given":"Massimo","family":"Fantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku","family":"Miettinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Fetsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Peer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Figg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Houston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Lipkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslava","family":"Pavelova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin N.","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Trewhitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Brooke","family":"Solarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fergusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon A.","family":"Mavroukakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjum","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwong Y.","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M.","family":"Arlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"2649_CR1","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1172\/JCI83871","volume":"125","author":"Y Yang","year":"2015","unstructured":"Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015;125:3335\u20137.","journal-title":"J Clin Invest"},{"key":"2649_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u20134.","journal-title":"Nat Rev Cancer"},{"key":"2649_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3389\/fimmu.2019.00481","volume":"10","author":"I Teige","year":"2019","unstructured":"Teige I, M\u00e5rtensson L, Frend\u00e9us BL. Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on Fc\u03b3RIIB. Front Immunol. 2019;10:481.","journal-title":"Front Immunol"},{"key":"2649_CR4","doi-asserted-by":"publisher","first-page":"110693","DOI":"10.18632\/oncotarget.22690","volume":"8","author":"J Bai","year":"2017","unstructured":"Bai J, Gao Z, Li X, Dong L, Han W, Nie J. Regulation of PD-1\/PD-L1 pathway and resistance to PD-1\/PD-L1 blockade. Oncotarget. 2017;8:110693\u2013707.","journal-title":"Oncotarget"},{"key":"2649_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3389\/fimmu.2013.00076","volume":"4","author":"UJ Seidel","year":"2013","unstructured":"Seidel UJ, Schlegel P, Lang P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol. 2013;4:76.","journal-title":"Front Immunol"},{"key":"2649_CR6","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1517\/14712598.8.6.759","volume":"8","author":"SY Wang","year":"2008","unstructured":"Wang SY, Weiner G. Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opin Biol Ther. 2008;8:759\u201368.","journal-title":"Expert Opin Biol Ther"},{"key":"2649_CR7","first-page":"1727","volume":"12","author":"Monoclonal antibody approved for metastatic breast cancer","year":"1998","unstructured":"Monoclonal antibody approved for metastatic breast cancer. Oncology (Williston Park). 1998;12:1727.","journal-title":"Oncology (Williston Park)"},{"issue":"Suppl 8","key":"2649_CR8","first-page":"63","volume":"12","author":"DG Maloney","year":"1998","unstructured":"Maloney DG, Press OW. Newer treatments for non-Hodgkin\u2019s lymphoma: monoclonal antibodies. Oncology (Williston Park). 1998;12(Suppl 8):63\u201376.","journal-title":"Oncology (Williston Park)"},{"key":"2649_CR9","unstructured":"Lacouture ME, Melosky BL. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Therapy Lett. 2007;12:1\u20135."},{"key":"2649_CR10","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s40265-017-0749-6","volume":"77","author":"ES Kim","year":"2017","unstructured":"Kim ES. Avelumab: First Global Approval. Drugs. 2017;77:929\u201337.","journal-title":"Drugs"},{"key":"2649_CR11","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/15384047.2020.1844117","volume":"21","author":"A Erck","year":"2020","unstructured":"Erck A, Aragon-Ching JB. Maintenance avelumab for metastatic urothelial cancer: a new standard of care. Cancer Biol Ther. 2020;21:1095\u20136.","journal-title":"Cancer Biol Ther"},{"key":"2649_CR12","doi-asserted-by":"publisher","first-page":"E34","DOI":"10.3390\/antib9030034","volume":"9","author":"D Zahavi","year":"2020","unstructured":"Zahavi D, Weiner L. Monoclonal Antibodies in Cancer Therapy. Antibodies Basel Switz. 2020;9:E34.","journal-title":"Antibodies Basel Switz"},{"key":"2649_CR13","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.3389\/fimmu.2017.01899","volume":"8","author":"M Fantini","year":"2018","unstructured":"Fantini M, David JM, Saric O, Dubeykovskiy A, Cui Y, Mavroukakis SA, et al. Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas. Front Immunol. 2018;8:1899.","journal-title":"Front Immunol"},{"key":"2649_CR14","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3389\/fonc.2020.00805","volume":"10","author":"KP Zeligs","year":"2020","unstructured":"Zeligs KP, Morelli MP, David JM, Neuman M, Hernandez L, Hewitt S, et al. Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer. Front Oncol. 2020;10:805.","journal-title":"Front Oncol"},{"key":"2649_CR15","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.3390\/cancers14133037","volume":"14","author":"KY Tsang","year":"2022","unstructured":"Tsang KY, Fantini M, Mavroukakis SA, Zaki A, Annunziata CM, Arlen PM. Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas. Cancers (Basel). 2022;14:3037.","journal-title":"Cancers (Basel)"},{"key":"2649_CR16","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.bbagen.2016.03.008","volume":"1860","author":"J Chia","year":"2016","unstructured":"Chia J, Goh G, Bard F. Short O-GalNAc glycans: Regulation and role in tumor development and clinical perspectives. Biochim Biophys Acta. 2016;1860:1623\u201339.","journal-title":"Biochim Biophys Acta"},{"key":"2649_CR17","doi-asserted-by":"publisher","first-page":"4999","DOI":"10.3390\/cancers14204999","volume":"14","author":"KY Tsang","year":"2022","unstructured":"Tsang KY, Fantini M, Zaki A, Mavroukakis SA, Morelli MP, Annunziata CM, Arlen PM. Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201. Cancers. 2022;14:4999.","journal-title":"Cancers"},{"key":"2649_CR18","first-page":"147","volume":"34","author":"M Fantini","year":"2019","unstructured":"Fantini M, David JM, Wong HC, Annunziata CM, Arlen PM, Tsang KY. An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells. Cancer Biother Radiopharm. 2019;34:147\u201359.","journal-title":"Cancer Biother Radiopharm"},{"key":"2649_CR19","first-page":"190","volume":"35","author":"M Fantini","year":"2020","unstructured":"Fantini M, David JM, Annunziata CM, Morelli MP, Arlen PM, Tsang KY. The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5\/CEACAM1 Immune Checkpoint Pathway. Cancer Biother Radiopharm. 2020;35:190\u20138.","journal-title":"Cancer Biother Radiopharm"},{"key":"2649_CR20","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman JT, Meibohm B. Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacomet Syst Pharmacol. 2017;6:576\u201388.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"2649_CR21","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.3390\/cancers13174280","volume":"13","author":"B Honrubia-Peris","year":"2021","unstructured":"Honrubia-Peris B, Garde-Noguera J, Garc\u00eda-S\u00e1nchez J, Piera-Molons N, Llombart-Cussac A, Fern\u00e1ndez-Murga ML. Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy. Cancers. 2021;13:4280.","journal-title":"Cancers"},{"key":"2649_CR22","doi-asserted-by":"publisher","first-page":"6584","DOI":"10.1158\/0008-5472.CAN-13-0123","volume":"73","author":"KH Bramswig","year":"2013","unstructured":"Bramswig KH, Poettler M, Unseld M, Wrba F, Uhrin P, Zimmermann W, et al. Soluble carcinoembryonic antigen activates endothelial cells and tumor angiogenesis. Cancer Res. 2013;73:6584\u201396.","journal-title":"Cancer Res"},{"key":"2649_CR23","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/ijc.21382","volume":"118","author":"S Holdenrieder","year":"2006","unstructured":"Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICA in malignant diseases. Int J Cancer. 2006;118:684\u20137.","journal-title":"Int J Cancer"},{"key":"2649_CR24","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1002\/mc.22667","volume":"56","author":"G Onyeaghala","year":"2017","unstructured":"Onyeaghala G, Nelson HH, Thyagarajan B, Linabery AM, Panoskaltsis-Mortari A, Gross M, et al. Soluble MICA is elevated in pancreatic cancer: Results from a population based case-control study. Mol Carcinog. 2017;56:2158\u201364.","journal-title":"Mol Carcinog"},{"key":"2649_CR25","doi-asserted-by":"publisher","first-page":"e1230","DOI":"10.1002\/cti2.1230","volume":"9","author":"S Xing","year":"2020","unstructured":"Xing S, de FerrariAndrade L. NKG2D and MICA\/B shedding: a \u201ctag game\u201d between NK cells and malignant cells. Clin Transl Immunol. 2020;9:e1230.","journal-title":"Clin Transl Immunol."},{"key":"2649_CR26","doi-asserted-by":"publisher","first-page":"118","DOI":"10.14336\/AD.2019.1017","volume":"11","author":"Q Luo","year":"2020","unstructured":"Luo Q, Luo W, Zhu Q, Huang H, Peng H, Liu R, et al. Tumor-Derived Soluble MICA Obstructs the NKG2D Pathway to Restrain NK Cytotoxicity. Aging Dis. 2020;11:118\u201328.","journal-title":"Aging Dis"},{"key":"2649_CR27","doi-asserted-by":"publisher","first-page":"7225","DOI":"10.1073\/pnas.1508224112","volume":"112","author":"M Miyara","year":"2015","unstructured":"Miyara M, Chader D, Sage E, Sugiyama D, Nishikawa H, Bouvry D, et al. Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3high regulatory T cells in humans. Proc Natl Acad Sci U S A. 2015;112:7225\u201330.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2649_CR28","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc3982","volume":"15","author":"SS Pinho","year":"2015","unstructured":"Pinho SS, Reis CA. Glycosylation in cancer: Mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540\u201355.","journal-title":"Nat Rev Cancer"},{"key":"2649_CR29","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1053\/hupa.2000.9776","volume":"31","author":"B Davidson","year":"2000","unstructured":"Davidson B, Berner A, Nesland JM, Risberg B, Kristensen GB, Trop\u00e9 CG, et al. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: Evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions. Hum Pathol. 2000;31:1081\u20137.","journal-title":"Hum Pathol"},{"key":"2649_CR30","doi-asserted-by":"publisher","first-page":"6885","DOI":"10.1111\/jcmm.14572","volume":"23","author":"D Thomas","year":"2019","unstructured":"Thomas D, Sagar S, Caffrey T, Grandgenett PM, Radhakrishnan P. Truncated O-glycans promote epithelial-to-mesenchymal transition and stemness properties of pancreatic cancer cells. J Cell Mol Med. 2019;23:6885\u201396.","journal-title":"J Cell Mol Med"},{"key":"2649_CR31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/bs.acr.2014.11.002","volume":"126","author":"MR Kudelka","year":"2015","unstructured":"Kudelka MR, Ju T, Heimburg-Molinaro J, Cummings RD. Simple sugars to complex disease\u2013mucin-type O-glycans in cancer. Adv Cancer Res. 2015;126:53\u2013135.","journal-title":"Adv Cancer Res"},{"key":"2649_CR32","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3389\/fonc.2018.00364","volume":"8","author":"X Pang","year":"2018","unstructured":"Pang X, Li H, Guan F, Li X. Multiple Roles of Glycans in Hematological Malignancies. Front Oncol. 2018;8:364.","journal-title":"Front Oncol"},{"key":"2649_CR33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/112_2021_60","volume":"180","author":"H Su","year":"2021","unstructured":"Su H, Wang M, Pang X, Guan F, Li X, Cheng Y. When Glycosylation Meets Blood Cells: A Glance of the Aberrant Glycosylation in Hematological Malignancies. Rev Physiol Biochem Pharmacol. 2021;180:85\u2013117.","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"2649_CR34","first-page":"480","volume":"56","author":"A Hollinshead","year":"1985","unstructured":"Hollinshead A, Elias EG, Arlen M, Buda B, Mosley M, Scherrer J. Specific active immunotherapy in patients with adenocarcinoma of the colon utilizing tumor-associated antigens (TAA). A phase I clinical trial. Cancer. 1985;56:480\u20139.","journal-title":"A phase I clinical trial Cancer"},{"issue":"Suppl 2","key":"2649_CR35","doi-asserted-by":"publisher","first-page":"A925","DOI":"10.1136\/jitc-2021-SITC2021.883","volume":"9","author":"A Romano","year":"2021","unstructured":"Romano A, Parrinello N, Marino S, La Spina E, Fantini M, Arlen PM, et al. An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target human acute myeloid leukemia (AML) cell lines in vitro. J Immunother Cancer. 2021;9(Suppl 2):A925.","journal-title":"J Immunother Cancer"},{"key":"2649_CR36","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.3389\/fimmu.2019.01818","volume":"10","author":"A Montfort","year":"2019","unstructured":"Montfort A, Colacios C, Levade T, Andrieu-Abadie N, Meyer N, S\u00e9gui B. The TNF Paradox in Cancer Progression and Immunotherapy. Front Immunol. 2019;10:1818.","journal-title":"Front Immunol"},{"key":"2649_CR37","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/2326-6066.CIR-13-0214","volume":"2","author":"M Oft","year":"2014","unstructured":"Oft M. IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity. Cancer Immunol Res. 2014;2:194\u20139.","journal-title":"Cancer Immunol Res"},{"key":"2649_CR38","doi-asserted-by":"publisher","first-page":"633205","DOI":"10.3389\/fimmu.2021.633205","volume":"12","author":"C Zalfa","year":"2021","unstructured":"Zalfa C, Paust S. Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy. Front Immunol. 2021;12:633205.","journal-title":"Front Immunol"},{"key":"2649_CR39","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.immuni.2019.01.020","volume":"50","author":"JB Wing","year":"2019","unstructured":"Wing JB, Tanaka A, Sakaguchi S. Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer. Immunity. 2019;50:302\u201316.","journal-title":"Immunity"},{"key":"2649_CR40","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942\u20139.","journal-title":"Nat Med"},{"key":"2649_CR41","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1158\/0008-5472.CAN-11-3468","volume":"72","author":"V Sisirak","year":"2012","unstructured":"Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, et al. Impaired IFN-\u03b1 production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res. 2012;72:5188\u201397.","journal-title":"Cancer Res"},{"key":"2649_CR42","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1038\/onc.2016.458","volume":"36","author":"X Wang","year":"2017","unstructured":"Wang X, Lang M, Zhao T, Feng X, Zheng C, Huang C, et al. Cancer-FOXP3 directly activated CCL5 to recruit FOXP3+Treg cells in pancreatic ductal adenocarcinoma. Oncogene. 2017;36:3048\u201358.","journal-title":"Oncogene"},{"key":"2649_CR43","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/ni.3868","volume":"18","author":"T Maj","year":"2017","unstructured":"Maj T, Wang W, Crespo J, Zhang H, Wang W, Wei S, et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol. 2017;18:1332\u201341.","journal-title":"Nat Immunol"},{"key":"2649_CR44","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12865-021-00451-7","volume":"22","author":"F Xu","year":"2021","unstructured":"Xu F, Zhang F, Wang Q, Xu Y, Xu S, Zhang C, et al. The augment of regulatory T cells undermines the efficacy of anti-PD-L1 treatment in cervical cancer. BMC Immunol. 2021;22:60.","journal-title":"BMC Immunol"},{"key":"2649_CR45","doi-asserted-by":"publisher","first-page":"e13129","DOI":"10.1111\/sji.13129","volume":"95","author":"G Zhulai","year":"2022","unstructured":"Zhulai G, Oleinik E. Targeting regulatory T cells in anti-PD-1\/PD-L1 cancer immunotherapy. Scand J Immunol. 2022;95:e13129.","journal-title":"Scand J Immunol"},{"issue":"Suppl 2","key":"2649_CR46","first-page":"A637","volume":"10","author":"P Mark-Adjeli","year":"2022","unstructured":"Mark-Adjeli P, Annunziata C, Cole C, Morelli MP, McCoy A, Fantini M, et al. Phase IIa combining NEO-201 with pembrolizumab in adults with chemo-resistant solid tumors. J Immunother Cancer. 2022;10(Suppl 2):A637.","journal-title":"J Immunother Cancer"},{"key":"2649_CR47","doi-asserted-by":"publisher","first-page":"1016646","DOI":"10.3389\/fimmu.2022.1016646","volume":"13","author":"J Shan","year":"2022","unstructured":"Shan J, Han D, Shen C, Lei Q, Zhang Y. Mechanism and strategies of immunotherapy resistance in colorectal cancer. Front Immunol. 2022;13:1016646.","journal-title":"Front Immunol"},{"issue":"Suppl 4","key":"2649_CR48","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1200\/JCO.2023.41.4_suppl.4","volume":"41","author":"J Tabernero","year":"2023","unstructured":"Tabernero J, Prager GW, Fakih M, Ciardiello F, Cutsem EV, Elez E, et al. Trifluridine\/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study. J Clin Oncol. 2023;41(Suppl 4):4\u20134.","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1186\/s13046-023-02668-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000}}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02649-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-023-02649-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02649-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T05:09:22Z","timestamp":1682485762000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-023-02649-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2649"],"URL":"https:\/\/doi.org\/10.1186\/s13046-023-02649-6","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]},"assertion":[{"value":"9 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13046-023-02668-3","URL":"https:\/\/doi.org\/10.1186\/s13046-023-02668-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by NCI, NIH, Institutional Review Board (protocol code NCT03476681, first approved 03\/26\/2018; latest update 01\/08\/2020) and all participants signed a written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All data generated or analyzed during this study are included in this published article [and its supplementary information files].Data not shown in the manuscript are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"All patients gave written informed consent.All authors have read and approved of its submission to this journal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MF, SAM, AZ, KYT and PMA are employees of Precision Biologics, Inc. PMA has an ownership interest in Precision Biologics, Inc. PMA had no role in the design of the study, in the collection, analyses or interpretation of the data, in the writing of the manuscript or in the decision to publish the results. All other authors have no conflicts of interest to declare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}